πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10464967

Non-hormonal steroid modulators of NF-ΞΊΞ² for treatment of disease

ReveraGen BioPharma, Inc. Β· Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10463655

Method of treatment with tradipitant

VANDA PHARMACEUTICALS INC. Β· Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457676

Capsazepine analogs for the treatment of cancer and other proliferative diseases

The Board of Regents of the University of Texas System Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10457670

Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric m

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10456439

NK3 agonist for use in the treatment of a patient suffering from atrial arrhythmia or fibr

ACADEMISCH MEDISCH CENTRUM Β· Granted Tue Oct 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10450364

Hyperimmunized egg product for treatment of necrotic enteritis in poultry

United States of America as represented by the Secretary of the Air Force Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449191

Treatment of prostate cancer

Takeda Pharmaceutical Company Limited Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449176

Treatment of circadian rhythm disorders

VANDA PHARMACEUTICALS INC. Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449171

Compositions and methods for diagnosis and treatment of metabolic syndrome

The United States of America, as represented by Secretary of the Navy Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10449170

Compositions for diagnosis and treatment of type 2 diabetes

The United States of America, as represented by Secretary of the Navy Β· Granted Tue Oct 22 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 17 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10442852

Methods and compositions for treatment of symptoms associated with intracranial hemorrhage

The Board of Regents of the University of Texas System Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441614

Compositions and methods for the treatment of wounds, disorders, and diseases of the skin

Krystal Biotech, Inc. Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10441580

Iloperidone for the treatment of schizophrenia

VANDA PHARMACEUTICALS INC. Β· Granted Tue Oct 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10435428

Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory diseas

Theravance Biopharma R&D IP, LLC Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434134

Peptide treatment for inflammation and fibrosis

The Regents of the University of California Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434078

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA co

The Regents of the University of California Β· Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428057

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of

The Board of Regents of the University of Texas System Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426817

Treatment of age-related macular degeneration and other eye diseases with apolipoprotein m

MacRegen, Inc. Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426790

Treatment of allergic eye conditions with cyclodextrins

Aldeyra Therapeutics, Inc. Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426771

6-hydroxy-2,5,7,8-tetramethylchroman-compounds for the treatment of chronic obstructive ai

Sulfateq B.V. Β· Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420793

Composition of novel carbohydrate drug for treatment of human diseases

GALECTIN THERAPEUTICS, INC. Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420748

Methods of treatment associated with the granulocyte colony-stimulating factor receptor

Ligand Pharmaceuticals Incorporated Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420747

Cancer treatment method using ailanthone compounds

EAST CHINA NORMAL UNIVERSITY Β· Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10416163

Method and treatment of recurring endometrial cancer with an inhibitor of USP14

Regents of the University of Minnesota Β· Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted